In an era when healthcare continues to evolve rapidly, Verantos has positioned itself as a transformative force in the field of real-world evidence (RWE). Founded by a visionary doctor with a deep understanding of healthcare and technology, Verantos has become a leading provider of high-quality real-world data and high-validity evidence to life sciences organizations, playing a pivotal role in improving patient outcomes, drug development, and clinical decision-making.
The Inception of Verantos
Verantos was born out of a desire to enable a learning health system that could harness real-world data to drive better healthcare outcomes. Founded by a physician who had built and sold several companies and is an expert in healthcare AI, Verantos’ creation was inspired by the opportunities presented by the 21st Century Cures Act. This landmark legislation, which focused on advancing healthcare technology and the use of real-world evidence, laid the groundwork for the creation of Verantos.
The company was founded on the principle that routine health data, combined with technological advancements, could be used to generate high-validity evidence to improve patient care. Harnessing the power of electronic health records (EHRs), artificial intelligence (AI), and cloud computing, Verantos seeks to transform healthcare decision-making. With several top 10 life sciences firms as customers, and backing from prestigious organizations like the National Institutes of Health (NIH), the National Science Foundation (NSF), and the Food and Drug Administration (FDA), Verantos has quickly gained recognition as a Silicon Valley success story dedicated to improving healthcare outcomes.
Addressing Key Trends in Healthcare
As the healthcare landscape evolves, Verantos has positioned itself at the forefront of several critical trends shaping the industry. One of the most significant shifts in healthcare is the increasing complexity of patients. Not only are there multiple options for treatment, but emerging treatments are very precisely targeted.
Verantos’ advantage lies in its ability to provide rich reliable, high-quality real-world data, offering a means for life sciences organizations to generate high-validity real-world evidence (RWE). Payers, healthcare providers, and regulators can then use this information to make more informed decisions based on real-world clinical outcomes. The company’s proprietary technologies and methodologies enable life sciences firms, payers, providers, and regulators to access reliable data that reflects real-world effectiveness, providing insights into which treatments work best for specific patients.
Technological Advancements Driving Verantos’ Success
Every 50 years, most industries undergo a meaningful transformation. On each transformation, there are enabling technologies and then a disruptive change. Earlier sea changes included: germ theory in the 1870s, penicillin in the 1920s, and evidence-based medicine and the randomized controlled trial paradigm in the 1970s. Each was based on preceding enabling technology.
As of the 2020s, the enabling technologies are electronic health records, recent breakthroughs in artificial intelligence, and the massive computing resources available through the cloud. The enabled transformation will be personalized medicine, with care being tailored to individual traits based on extensive experience from prior clinical care.
Enabling technologies, combined with strict adherence to methodologies emphasizing data reliability, allow Verantos to lead the market in scalable high-quality real-world data and high-validity real-world evidence that supports personalized medicine.
Key Milestones and Achievements
In the past year, Verantos has achieved several significant milestones that highlight its impact on the healthcare industry:
- Launch of the Inflammatory Bowel Disease (IBD) Pragmatic Registry: This registry, now in use by leading pharmaceutical companies, is helping shape the future of care for millions of Americans living with IBD.
- Launch of the Alzheimer’s Disease Pragmatic Registry: Verantos’ Alzheimer’s Disease registry provides unprecedented data for researchers, offering insights that were previously unavailable.
- Expansion of the Customer Base: Verantos continues to attract top-tier clients, including Bayer Pharmaceuticals, cementing its reputation as a leader in real-world evidence.
- Recognition on the Inc. 5000 List: For the third consecutive year, Verantos was featured on the Inc. 5000 list of the fastest-growing private companies in America; Verantos is the only RWE company on the list.
Core Contributions to Healthcare
Verantos has brought two flagship products to market: Pragmatic Registry and Observational Research. Each product is designed to offer life sciences companies and healthcare organizations access to high-quality, customizable data sets that inform clinical decisions and research efforts.
- Pragmatic Registry: A disease-specific registry generated from real-world data, Pragmatic Registry allows life sciences firms to subscribe to datasets that represent specific patient cohorts. Key advantages include scalability, flexibility, and cost-efficiency, making it an ideal solution for firms looking to understand healthcare resource utilization and patient outcomes.
- Observational Research: A services-based product that enables companies to generate high-validity real-world evidence, Observational Research supports the development of credible evidence needed for regulatory approval, provider decision-making, and payer assessments.
The success of Verantos lies in its ability to offer data of unparalleled richness and reliability. Unlike legacy vendors that rely on high-volume, low-quality data, Verantos uses curation, linkage, and enrichment to achieve rich and reliable data. This focus on richness and reliability is critical for life sciences firms that need credible evidence to market their products and meet regulatory requirements.
Future Plans
Looking ahead, Verantos aims to expand its product offerings while maintaining its focus on enabling a learning healthcare system. The company plans to enhance its Verantos Evidence Platform, expand AI capabilities to simplify complex tasks, and broaden its Verantos Research Network to include more health systems, thereby offering even greater visibility into the patient journey.
Verantos remains committed to advancing healthcare by using high-validity real-world evidence to inform treatment decisions, support life sciences companies, and inform regulatory decision-making. By continually pushing the boundaries of what’s possible with healthcare data, Verantos is poised to shape the future of research and development, drug approval, and patient care.
